In Vitro Activity of a New Antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae
Open Access
- 1 April 2003
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (4) , 1447-1448
- https://doi.org/10.1128/aac.47.4.1447-1448.2003
Abstract
The in vitro activity of NVP-PDF386 (VRC4887), a novel new peptide deformylase inhibitor, and those of levofloxacin and clarithromycin were tested against 21 isolates of Chlamydia pneumoniae . The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by NVP-PDF386 for all isolates of C. pneumoniae were 0.008 μg/ml (range, 0.008 to 0.015 μg/ml) compared to 0.25 and 0.06 μg/ml for levofloxacin and clarithromycin, respectively.Keywords
This publication has 4 references indexed in Scilit:
- In Vitro Activities of Peptide Deformylase Inhibitors against Gram-Positive PathogensAntimicrobial Agents and Chemotherapy, 2002
- In Vitro Activities of BMS-284756 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniaeAntimicrobial Agents and Chemotherapy, 2002
- Deformylase as a novel antibacterial targetDrug Discovery Today, 2001
- In Vitro Activity of ABT 773, a New Ketolide Antibiotic, against Chlamydia pneumoniaeAntimicrobial Agents and Chemotherapy, 2000